nodes	percent_of_prediction	percent_of_DWPC	metapath
Etoricoxib—Vemurafenib—melanoma	0.694	1	CrCtD
Etoricoxib—PTGS2—melanoma	0.0718	1	CbGaD
Etoricoxib—CYP2E1—Dacarbazine—melanoma	0.024	0.194	CbGbCtD
Etoricoxib—CYP1A2—Carmustine—melanoma	0.0229	0.185	CbGbCtD
Etoricoxib—CYP1A2—Vemurafenib—melanoma	0.0181	0.146	CbGbCtD
Etoricoxib—CYP3A4—Temozolomide—melanoma	0.0173	0.14	CbGbCtD
Etoricoxib—CYP2D6—Vemurafenib—melanoma	0.0149	0.12	CbGbCtD
Etoricoxib—CYP1A2—Dacarbazine—melanoma	0.0139	0.112	CbGbCtD
Etoricoxib—CYP3A4—Vemurafenib—melanoma	0.00949	0.0766	CbGbCtD
Etoricoxib—CYP3A4—Docetaxel—melanoma	0.00326	0.0263	CbGbCtD
Etoricoxib—Vemurafenib—BRAF—melanoma	0.00116	0.615	CrCbGaD
Etoricoxib—MAPK14—hair follicle—melanoma	0.000689	0.152	CbGeAlD
Etoricoxib—MAPK14—blood vessel—melanoma	0.000646	0.142	CbGeAlD
Etoricoxib—MAPK14—neck—melanoma	0.000462	0.102	CbGeAlD
Etoricoxib—PTGS2—leg—melanoma	0.000435	0.0959	CbGeAlD
Etoricoxib—PTGS2—hindlimb—melanoma	0.000389	0.0857	CbGeAlD
Etoricoxib—PTGS2—appendage—melanoma	0.000334	0.0735	CbGeAlD
Etoricoxib—MAPK14—skin of body—melanoma	0.000299	0.0659	CbGeAlD
Etoricoxib—PTGS2—skin epidermis—melanoma	0.000277	0.0611	CbGeAlD
Etoricoxib—Vemurafenib—ALB—melanoma	0.000224	0.119	CrCbGaD
Etoricoxib—PTGS2—endothelium—melanoma	0.000201	0.0444	CbGeAlD
Etoricoxib—MAPK14—head—melanoma	0.000195	0.043	CbGeAlD
Etoricoxib—PTGS2—blood vessel—melanoma	0.000186	0.0409	CbGeAlD
Etoricoxib—Celecoxib—PTGS2—melanoma	0.000148	0.0786	CrCbGaD
Etoricoxib—MAPK14—lymph node—melanoma	0.000137	0.0301	CbGeAlD
Etoricoxib—Celecoxib—ALB—melanoma	0.000132	0.07	CrCbGaD
Etoricoxib—Vismodegib—ALB—melanoma	0.000113	0.06	CrCbGaD
Etoricoxib—Vismodegib—ABCB1—melanoma	0.000108	0.0573	CrCbGaD
Etoricoxib—Atrial fibrillation—Docetaxel—melanoma	9.91e-05	0.00201	CcSEcCtD
Etoricoxib—Visual disturbance—Docetaxel—melanoma	9.91e-05	0.00201	CcSEcCtD
Etoricoxib—Renal impairment—Docetaxel—melanoma	9.87e-05	0.002	CcSEcCtD
Etoricoxib—Haemoglobin—Temozolomide—melanoma	9.82e-05	0.00199	CcSEcCtD
Etoricoxib—Hepatitis—Temozolomide—melanoma	9.77e-05	0.00198	CcSEcCtD
Etoricoxib—Haemorrhage—Temozolomide—melanoma	9.77e-05	0.00198	CcSEcCtD
Etoricoxib—Asthenia—Vemurafenib—melanoma	9.74e-05	0.00197	CcSEcCtD
Etoricoxib—Visual impairment—Carmustine—melanoma	9.74e-05	0.00197	CcSEcCtD
Etoricoxib—Hypoaesthesia—Temozolomide—melanoma	9.72e-05	0.00197	CcSEcCtD
Etoricoxib—Hallucination—Temozolomide—melanoma	9.72e-05	0.00197	CcSEcCtD
Etoricoxib—Pharyngitis—Temozolomide—melanoma	9.69e-05	0.00196	CcSEcCtD
Etoricoxib—Urinary tract disorder—Temozolomide—melanoma	9.65e-05	0.00195	CcSEcCtD
Etoricoxib—Oedema peripheral—Temozolomide—melanoma	9.62e-05	0.00195	CcSEcCtD
Etoricoxib—Pruritus—Vemurafenib—melanoma	9.61e-05	0.00194	CcSEcCtD
Etoricoxib—Connective tissue disorder—Temozolomide—melanoma	9.6e-05	0.00194	CcSEcCtD
Etoricoxib—Urethral disorder—Temozolomide—melanoma	9.58e-05	0.00194	CcSEcCtD
Etoricoxib—Alopecia—Dactinomycin—melanoma	9.54e-05	0.00193	CcSEcCtD
Etoricoxib—Eye disorder—Carmustine—melanoma	9.45e-05	0.00191	CcSEcCtD
Etoricoxib—Visual impairment—Temozolomide—melanoma	9.41e-05	0.00191	CcSEcCtD
Etoricoxib—Erythema—Dactinomycin—melanoma	9.4e-05	0.0019	CcSEcCtD
Etoricoxib—Gastrointestinal haemorrhage—Docetaxel—melanoma	9.39e-05	0.0019	CcSEcCtD
Etoricoxib—Pain in extremity—Docetaxel—melanoma	9.39e-05	0.0019	CcSEcCtD
Etoricoxib—Flushing—Carmustine—melanoma	9.38e-05	0.0019	CcSEcCtD
Etoricoxib—Anaemia—Bleomycin—melanoma	9.32e-05	0.00189	CcSEcCtD
Etoricoxib—Diarrhoea—Vemurafenib—melanoma	9.29e-05	0.00188	CcSEcCtD
Etoricoxib—Erythema multiforme—Temozolomide—melanoma	9.24e-05	0.00187	CcSEcCtD
Etoricoxib—Eye disorder—Temozolomide—melanoma	9.13e-05	0.00185	CcSEcCtD
Etoricoxib—Tinnitus—Temozolomide—melanoma	9.11e-05	0.00184	CcSEcCtD
Etoricoxib—Cardiac disorder—Temozolomide—melanoma	9.07e-05	0.00184	CcSEcCtD
Etoricoxib—Flushing—Temozolomide—melanoma	9.07e-05	0.00184	CcSEcCtD
Etoricoxib—Arrhythmia—Carmustine—melanoma	9.03e-05	0.00183	CcSEcCtD
Etoricoxib—Dizziness—Vemurafenib—melanoma	8.98e-05	0.00182	CcSEcCtD
Etoricoxib—Alopecia—Carmustine—melanoma	8.93e-05	0.00181	CcSEcCtD
Etoricoxib—Angiopathy—Temozolomide—melanoma	8.86e-05	0.00179	CcSEcCtD
Etoricoxib—Mental disorder—Carmustine—melanoma	8.86e-05	0.00179	CcSEcCtD
Etoricoxib—Immune system disorder—Temozolomide—melanoma	8.82e-05	0.00179	CcSEcCtD
Etoricoxib—Mediastinal disorder—Temozolomide—melanoma	8.8e-05	0.00178	CcSEcCtD
Etoricoxib—Malnutrition—Carmustine—melanoma	8.8e-05	0.00178	CcSEcCtD
Etoricoxib—Erythema—Carmustine—melanoma	8.8e-05	0.00178	CcSEcCtD
Etoricoxib—Cough—Bleomycin—melanoma	8.8e-05	0.00178	CcSEcCtD
Etoricoxib—Anaemia—Dactinomycin—melanoma	8.69e-05	0.00176	CcSEcCtD
Etoricoxib—Vomiting—Vemurafenib—melanoma	8.63e-05	0.00175	CcSEcCtD
Etoricoxib—Alopecia—Temozolomide—melanoma	8.63e-05	0.00175	CcSEcCtD
Etoricoxib—PTGS2—skin of body—melanoma	8.6e-05	0.0189	CbGeAlD
Etoricoxib—Chest pain—Bleomycin—melanoma	8.58e-05	0.00174	CcSEcCtD
Etoricoxib—Orthostatic hypotension—Docetaxel—melanoma	8.58e-05	0.00174	CcSEcCtD
Etoricoxib—Rash—Vemurafenib—melanoma	8.56e-05	0.00173	CcSEcCtD
Etoricoxib—Mental disorder—Temozolomide—melanoma	8.56e-05	0.00173	CcSEcCtD
Etoricoxib—Dermatitis—Vemurafenib—melanoma	8.55e-05	0.00173	CcSEcCtD
Etoricoxib—Headache—Vemurafenib—melanoma	8.51e-05	0.00172	CcSEcCtD
Etoricoxib—Malnutrition—Temozolomide—melanoma	8.5e-05	0.00172	CcSEcCtD
Etoricoxib—Erythema—Temozolomide—melanoma	8.5e-05	0.00172	CcSEcCtD
Etoricoxib—Breast disorder—Docetaxel—melanoma	8.49e-05	0.00172	CcSEcCtD
Etoricoxib—Cramp muscle—Docetaxel—melanoma	8.46e-05	0.00171	CcSEcCtD
Etoricoxib—Toxic epidermal necrolysis—Docetaxel—melanoma	8.46e-05	0.00171	CcSEcCtD
Etoricoxib—Aspartate aminotransferase increased—Docetaxel—melanoma	8.46e-05	0.00171	CcSEcCtD
Etoricoxib—Dysgeusia—Temozolomide—melanoma	8.33e-05	0.00169	CcSEcCtD
Etoricoxib—Confusional state—Bleomycin—melanoma	8.3e-05	0.00168	CcSEcCtD
Etoricoxib—Vision blurred—Carmustine—melanoma	8.29e-05	0.00168	CcSEcCtD
Etoricoxib—Alanine aminotransferase increased—Docetaxel—melanoma	8.28e-05	0.00168	CcSEcCtD
Etoricoxib—Tremor—Carmustine—melanoma	8.24e-05	0.00167	CcSEcCtD
Etoricoxib—Oedema—Bleomycin—melanoma	8.23e-05	0.00167	CcSEcCtD
Etoricoxib—Anaphylactic shock—Bleomycin—melanoma	8.23e-05	0.00167	CcSEcCtD
Etoricoxib—Infection—Bleomycin—melanoma	8.17e-05	0.00165	CcSEcCtD
Etoricoxib—Anaemia—Carmustine—melanoma	8.13e-05	0.00165	CcSEcCtD
Etoricoxib—Agitation—Carmustine—melanoma	8.09e-05	0.00164	CcSEcCtD
Etoricoxib—Nausea—Vemurafenib—melanoma	8.07e-05	0.00163	CcSEcCtD
Etoricoxib—Thrombocytopenia—Bleomycin—melanoma	8.06e-05	0.00163	CcSEcCtD
Etoricoxib—Vision blurred—Temozolomide—melanoma	8.01e-05	0.00162	CcSEcCtD
Etoricoxib—Bronchospasm—Docetaxel—melanoma	7.98e-05	0.00162	CcSEcCtD
Etoricoxib—Tremor—Temozolomide—melanoma	7.97e-05	0.00161	CcSEcCtD
Etoricoxib—Angina pectoris—Docetaxel—melanoma	7.91e-05	0.0016	CcSEcCtD
Etoricoxib—Anaemia—Temozolomide—melanoma	7.86e-05	0.00159	CcSEcCtD
Etoricoxib—Anorexia—Bleomycin—melanoma	7.84e-05	0.00159	CcSEcCtD
Etoricoxib—Agitation—Temozolomide—melanoma	7.81e-05	0.00158	CcSEcCtD
Etoricoxib—Angioedema—Temozolomide—melanoma	7.77e-05	0.00157	CcSEcCtD
Etoricoxib—Oedema—Dactinomycin—melanoma	7.67e-05	0.00155	CcSEcCtD
Etoricoxib—Infection—Dactinomycin—melanoma	7.62e-05	0.00154	CcSEcCtD
Etoricoxib—Hypertension—Carmustine—melanoma	7.6e-05	0.00154	CcSEcCtD
Etoricoxib—Palpitations—Temozolomide—melanoma	7.51e-05	0.00152	CcSEcCtD
Etoricoxib—Thrombocytopenia—Dactinomycin—melanoma	7.51e-05	0.00152	CcSEcCtD
Etoricoxib—Musculoskeletal discomfort—Bleomycin—melanoma	7.5e-05	0.00152	CcSEcCtD
Etoricoxib—Chest pain—Carmustine—melanoma	7.49e-05	0.00152	CcSEcCtD
Etoricoxib—Anxiety—Carmustine—melanoma	7.47e-05	0.00151	CcSEcCtD
Etoricoxib—Cough—Temozolomide—melanoma	7.42e-05	0.0015	CcSEcCtD
Etoricoxib—Weight increased—Docetaxel—melanoma	7.39e-05	0.0015	CcSEcCtD
Etoricoxib—Hypertension—Temozolomide—melanoma	7.34e-05	0.00149	CcSEcCtD
Etoricoxib—Dyspnoea—Bleomycin—melanoma	7.33e-05	0.00148	CcSEcCtD
Etoricoxib—Anorexia—Dactinomycin—melanoma	7.31e-05	0.00148	CcSEcCtD
Etoricoxib—Pneumonia—Docetaxel—melanoma	7.28e-05	0.00147	CcSEcCtD
Etoricoxib—Confusional state—Carmustine—melanoma	7.24e-05	0.00147	CcSEcCtD
Etoricoxib—Arthralgia—Temozolomide—melanoma	7.24e-05	0.00147	CcSEcCtD
Etoricoxib—Infestation—Docetaxel—melanoma	7.24e-05	0.00146	CcSEcCtD
Etoricoxib—Infestation NOS—Docetaxel—melanoma	7.24e-05	0.00146	CcSEcCtD
Etoricoxib—Anxiety—Temozolomide—melanoma	7.21e-05	0.00146	CcSEcCtD
Etoricoxib—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—melanoma	7.19e-05	0.00146	CcSEcCtD
Etoricoxib—Oedema—Carmustine—melanoma	7.18e-05	0.00145	CcSEcCtD
Etoricoxib—Stevens-Johnson syndrome—Docetaxel—melanoma	7.17e-05	0.00145	CcSEcCtD
Etoricoxib—Decreased appetite—Bleomycin—melanoma	7.15e-05	0.00145	CcSEcCtD
Etoricoxib—Infection—Carmustine—melanoma	7.13e-05	0.00144	CcSEcCtD
Etoricoxib—Acute coronary syndrome—Docetaxel—melanoma	7.13e-05	0.00144	CcSEcCtD
Etoricoxib—Renal failure—Docetaxel—melanoma	7.11e-05	0.00144	CcSEcCtD
Etoricoxib—Neuropathy peripheral—Docetaxel—melanoma	7.09e-05	0.00144	CcSEcCtD
Etoricoxib—Myocardial infarction—Docetaxel—melanoma	7.09e-05	0.00144	CcSEcCtD
Etoricoxib—Dry mouth—Temozolomide—melanoma	7.08e-05	0.00143	CcSEcCtD
Etoricoxib—Jaundice—Docetaxel—melanoma	7.05e-05	0.00143	CcSEcCtD
Etoricoxib—Stomatitis—Docetaxel—melanoma	7.05e-05	0.00143	CcSEcCtD
Etoricoxib—Pain—Bleomycin—melanoma	7.04e-05	0.00142	CcSEcCtD
Etoricoxib—Conjunctivitis—Docetaxel—melanoma	7.03e-05	0.00142	CcSEcCtD
Etoricoxib—Thrombocytopenia—Carmustine—melanoma	7.03e-05	0.00142	CcSEcCtD
Etoricoxib—Confusional state—Temozolomide—melanoma	7e-05	0.00142	CcSEcCtD
Etoricoxib—Musculoskeletal discomfort—Dactinomycin—melanoma	6.99e-05	0.00142	CcSEcCtD
Etoricoxib—Anaphylactic shock—Temozolomide—melanoma	6.94e-05	0.0014	CcSEcCtD
Etoricoxib—Oedema—Temozolomide—melanoma	6.94e-05	0.0014	CcSEcCtD
Etoricoxib—Infection—Temozolomide—melanoma	6.89e-05	0.0014	CcSEcCtD
Etoricoxib—Anorexia—Carmustine—melanoma	6.85e-05	0.00139	CcSEcCtD
Etoricoxib—Hepatobiliary disease—Docetaxel—melanoma	6.84e-05	0.00139	CcSEcCtD
Etoricoxib—Epistaxis—Docetaxel—melanoma	6.83e-05	0.00138	CcSEcCtD
Etoricoxib—Nervous system disorder—Temozolomide—melanoma	6.81e-05	0.00138	CcSEcCtD
Etoricoxib—Thrombocytopenia—Temozolomide—melanoma	6.79e-05	0.00138	CcSEcCtD
Etoricoxib—Feeling abnormal—Bleomycin—melanoma	6.78e-05	0.00137	CcSEcCtD
Etoricoxib—Skin disorder—Temozolomide—melanoma	6.74e-05	0.00136	CcSEcCtD
Etoricoxib—Decreased appetite—Dactinomycin—melanoma	6.67e-05	0.00135	CcSEcCtD
Etoricoxib—Fatigue—Dactinomycin—melanoma	6.62e-05	0.00134	CcSEcCtD
Etoricoxib—Anorexia—Temozolomide—melanoma	6.62e-05	0.00134	CcSEcCtD
Etoricoxib—Pain—Dactinomycin—melanoma	6.56e-05	0.00133	CcSEcCtD
Etoricoxib—Musculoskeletal discomfort—Carmustine—melanoma	6.54e-05	0.00132	CcSEcCtD
Etoricoxib—Urticaria—Bleomycin—melanoma	6.54e-05	0.00132	CcSEcCtD
Etoricoxib—Haemoglobin—Docetaxel—melanoma	6.53e-05	0.00132	CcSEcCtD
Etoricoxib—Hepatitis—Docetaxel—melanoma	6.5e-05	0.00132	CcSEcCtD
Etoricoxib—Haemorrhage—Docetaxel—melanoma	6.5e-05	0.00132	CcSEcCtD
Etoricoxib—Insomnia—Carmustine—melanoma	6.5e-05	0.00131	CcSEcCtD
Etoricoxib—Hypoaesthesia—Docetaxel—melanoma	6.46e-05	0.00131	CcSEcCtD
Etoricoxib—Pharyngitis—Docetaxel—melanoma	6.45e-05	0.00131	CcSEcCtD
Etoricoxib—Urinary tract disorder—Docetaxel—melanoma	6.42e-05	0.0013	CcSEcCtD
Etoricoxib—Dyspnoea—Carmustine—melanoma	6.4e-05	0.0013	CcSEcCtD
Etoricoxib—Oedema peripheral—Docetaxel—melanoma	6.4e-05	0.0013	CcSEcCtD
Etoricoxib—Somnolence—Carmustine—melanoma	6.38e-05	0.00129	CcSEcCtD
Etoricoxib—Connective tissue disorder—Docetaxel—melanoma	6.38e-05	0.00129	CcSEcCtD
Etoricoxib—Urethral disorder—Docetaxel—melanoma	6.37e-05	0.00129	CcSEcCtD
Etoricoxib—Feeling abnormal—Dactinomycin—melanoma	6.32e-05	0.00128	CcSEcCtD
Etoricoxib—Musculoskeletal discomfort—Temozolomide—melanoma	6.32e-05	0.00128	CcSEcCtD
Etoricoxib—Insomnia—Temozolomide—melanoma	6.28e-05	0.00127	CcSEcCtD
Etoricoxib—Gastrointestinal pain—Dactinomycin—melanoma	6.27e-05	0.00127	CcSEcCtD
Etoricoxib—Visual impairment—Docetaxel—melanoma	6.26e-05	0.00127	CcSEcCtD
Etoricoxib—Decreased appetite—Carmustine—melanoma	6.24e-05	0.00126	CcSEcCtD
Etoricoxib—Gastrointestinal disorder—Carmustine—melanoma	6.2e-05	0.00126	CcSEcCtD
Etoricoxib—Dyspnoea—Temozolomide—melanoma	6.19e-05	0.00125	CcSEcCtD
Etoricoxib—Somnolence—Temozolomide—melanoma	6.17e-05	0.00125	CcSEcCtD
Etoricoxib—Erythema multiforme—Docetaxel—melanoma	6.14e-05	0.00124	CcSEcCtD
Etoricoxib—Pain—Carmustine—melanoma	6.14e-05	0.00124	CcSEcCtD
Etoricoxib—Constipation—Carmustine—melanoma	6.14e-05	0.00124	CcSEcCtD
Etoricoxib—Dyspepsia—Temozolomide—melanoma	6.11e-05	0.00124	CcSEcCtD
Etoricoxib—CYP2E1—head—melanoma	6.09e-05	0.0134	CbGeAlD
Etoricoxib—Eye disorder—Docetaxel—melanoma	6.07e-05	0.00123	CcSEcCtD
Etoricoxib—Abdominal pain—Dactinomycin—melanoma	6.07e-05	0.00123	CcSEcCtD
Etoricoxib—Hypersensitivity—Bleomycin—melanoma	6.06e-05	0.00123	CcSEcCtD
Etoricoxib—Decreased appetite—Temozolomide—melanoma	6.03e-05	0.00122	CcSEcCtD
Etoricoxib—Cardiac disorder—Docetaxel—melanoma	6.03e-05	0.00122	CcSEcCtD
Etoricoxib—Flushing—Docetaxel—melanoma	6.03e-05	0.00122	CcSEcCtD
Etoricoxib—Gastrointestinal disorder—Temozolomide—melanoma	5.99e-05	0.00121	CcSEcCtD
Etoricoxib—Fatigue—Temozolomide—melanoma	5.98e-05	0.00121	CcSEcCtD
Etoricoxib—Pain—Temozolomide—melanoma	5.93e-05	0.0012	CcSEcCtD
Etoricoxib—Constipation—Temozolomide—melanoma	5.93e-05	0.0012	CcSEcCtD
Etoricoxib—Feeling abnormal—Carmustine—melanoma	5.92e-05	0.0012	CcSEcCtD
Etoricoxib—Asthenia—Bleomycin—melanoma	5.9e-05	0.00119	CcSEcCtD
Etoricoxib—Angiopathy—Docetaxel—melanoma	5.89e-05	0.00119	CcSEcCtD
Etoricoxib—Gastrointestinal pain—Carmustine—melanoma	5.87e-05	0.00119	CcSEcCtD
Etoricoxib—Immune system disorder—Docetaxel—melanoma	5.87e-05	0.00119	CcSEcCtD
Etoricoxib—Mediastinal disorder—Docetaxel—melanoma	5.85e-05	0.00119	CcSEcCtD
Etoricoxib—Pruritus—Bleomycin—melanoma	5.82e-05	0.00118	CcSEcCtD
Etoricoxib—Arrhythmia—Docetaxel—melanoma	5.8e-05	0.00117	CcSEcCtD
Etoricoxib—Alopecia—Docetaxel—melanoma	5.74e-05	0.00116	CcSEcCtD
Etoricoxib—Feeling abnormal—Temozolomide—melanoma	5.72e-05	0.00116	CcSEcCtD
Etoricoxib—Mental disorder—Docetaxel—melanoma	5.69e-05	0.00115	CcSEcCtD
Etoricoxib—Abdominal pain—Carmustine—melanoma	5.68e-05	0.00115	CcSEcCtD
Etoricoxib—Gastrointestinal pain—Temozolomide—melanoma	5.67e-05	0.00115	CcSEcCtD
Etoricoxib—Erythema—Docetaxel—melanoma	5.65e-05	0.00114	CcSEcCtD
Etoricoxib—Malnutrition—Docetaxel—melanoma	5.65e-05	0.00114	CcSEcCtD
Etoricoxib—Hypersensitivity—Dactinomycin—melanoma	5.65e-05	0.00114	CcSEcCtD
Etoricoxib—PTGS2—head—melanoma	5.61e-05	0.0124	CbGeAlD
Etoricoxib—Dysgeusia—Docetaxel—melanoma	5.54e-05	0.00112	CcSEcCtD
Etoricoxib—Urticaria—Temozolomide—melanoma	5.51e-05	0.00112	CcSEcCtD
Etoricoxib—Asthenia—Dactinomycin—melanoma	5.51e-05	0.00111	CcSEcCtD
Etoricoxib—Abdominal pain—Temozolomide—melanoma	5.49e-05	0.00111	CcSEcCtD
Etoricoxib—Muscle spasms—Docetaxel—melanoma	5.44e-05	0.0011	CcSEcCtD
Etoricoxib—Hypersensitivity—Carmustine—melanoma	5.29e-05	0.00107	CcSEcCtD
Etoricoxib—Diarrhoea—Dactinomycin—melanoma	5.25e-05	0.00106	CcSEcCtD
Etoricoxib—Vomiting—Bleomycin—melanoma	5.23e-05	0.00106	CcSEcCtD
Etoricoxib—Anaemia—Docetaxel—melanoma	5.23e-05	0.00106	CcSEcCtD
Etoricoxib—Rash—Bleomycin—melanoma	5.19e-05	0.00105	CcSEcCtD
Etoricoxib—Dermatitis—Bleomycin—melanoma	5.18e-05	0.00105	CcSEcCtD
Etoricoxib—Asthenia—Carmustine—melanoma	5.15e-05	0.00104	CcSEcCtD
Etoricoxib—Hypersensitivity—Temozolomide—melanoma	5.11e-05	0.00104	CcSEcCtD
Etoricoxib—Palpitations—Docetaxel—melanoma	5e-05	0.00101	CcSEcCtD
Etoricoxib—Asthenia—Temozolomide—melanoma	4.98e-05	0.00101	CcSEcCtD
Etoricoxib—Cough—Docetaxel—melanoma	4.93e-05	0.000999	CcSEcCtD
Etoricoxib—Diarrhoea—Carmustine—melanoma	4.91e-05	0.000995	CcSEcCtD
Etoricoxib—Pruritus—Temozolomide—melanoma	4.91e-05	0.000994	CcSEcCtD
Etoricoxib—Nausea—Bleomycin—melanoma	4.89e-05	0.000989	CcSEcCtD
Etoricoxib—Hypertension—Docetaxel—melanoma	4.88e-05	0.000988	CcSEcCtD
Etoricoxib—Vomiting—Dactinomycin—melanoma	4.88e-05	0.000988	CcSEcCtD
Etoricoxib—Rash—Dactinomycin—melanoma	4.84e-05	0.000979	CcSEcCtD
Etoricoxib—CYP2D6—head—melanoma	4.82e-05	0.0106	CbGeAlD
Etoricoxib—Arthralgia—Docetaxel—melanoma	4.81e-05	0.000975	CcSEcCtD
Etoricoxib—Chest pain—Docetaxel—melanoma	4.81e-05	0.000975	CcSEcCtD
Etoricoxib—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—melanoma	4.78e-05	0.000968	CcSEcCtD
Etoricoxib—Dizziness—Carmustine—melanoma	4.75e-05	0.000961	CcSEcCtD
Etoricoxib—Diarrhoea—Temozolomide—melanoma	4.75e-05	0.000961	CcSEcCtD
Etoricoxib—Dry mouth—Docetaxel—melanoma	4.71e-05	0.000953	CcSEcCtD
Etoricoxib—Confusional state—Docetaxel—melanoma	4.65e-05	0.000942	CcSEcCtD
Etoricoxib—Oedema—Docetaxel—melanoma	4.62e-05	0.000934	CcSEcCtD
Etoricoxib—Anaphylactic shock—Docetaxel—melanoma	4.62e-05	0.000934	CcSEcCtD
Etoricoxib—Dizziness—Temozolomide—melanoma	4.59e-05	0.000929	CcSEcCtD
Etoricoxib—Infection—Docetaxel—melanoma	4.58e-05	0.000928	CcSEcCtD
Etoricoxib—Vomiting—Carmustine—melanoma	4.57e-05	0.000924	CcSEcCtD
Etoricoxib—Nausea—Dactinomycin—melanoma	4.56e-05	0.000923	CcSEcCtD
Etoricoxib—Shock—Docetaxel—melanoma	4.54e-05	0.000919	CcSEcCtD
Etoricoxib—Rash—Carmustine—melanoma	4.53e-05	0.000917	CcSEcCtD
Etoricoxib—Nervous system disorder—Docetaxel—melanoma	4.53e-05	0.000916	CcSEcCtD
Etoricoxib—Dermatitis—Carmustine—melanoma	4.52e-05	0.000916	CcSEcCtD
Etoricoxib—Thrombocytopenia—Docetaxel—melanoma	4.52e-05	0.000915	CcSEcCtD
Etoricoxib—Headache—Carmustine—melanoma	4.5e-05	0.000911	CcSEcCtD
Etoricoxib—Skin disorder—Docetaxel—melanoma	4.48e-05	0.000907	CcSEcCtD
Etoricoxib—Vomiting—Temozolomide—melanoma	4.41e-05	0.000893	CcSEcCtD
Etoricoxib—Anorexia—Docetaxel—melanoma	4.4e-05	0.000891	CcSEcCtD
Etoricoxib—Rash—Temozolomide—melanoma	4.38e-05	0.000886	CcSEcCtD
Etoricoxib—Dermatitis—Temozolomide—melanoma	4.37e-05	0.000885	CcSEcCtD
Etoricoxib—Headache—Temozolomide—melanoma	4.35e-05	0.00088	CcSEcCtD
Etoricoxib—Nausea—Carmustine—melanoma	4.27e-05	0.000864	CcSEcCtD
Etoricoxib—Musculoskeletal discomfort—Docetaxel—melanoma	4.2e-05	0.000851	CcSEcCtD
Etoricoxib—Insomnia—Docetaxel—melanoma	4.17e-05	0.000845	CcSEcCtD
Etoricoxib—Nausea—Temozolomide—melanoma	4.12e-05	0.000834	CcSEcCtD
Etoricoxib—Dyspnoea—Docetaxel—melanoma	4.11e-05	0.000833	CcSEcCtD
Etoricoxib—Somnolence—Docetaxel—melanoma	4.1e-05	0.000831	CcSEcCtD
Etoricoxib—Dyspepsia—Docetaxel—melanoma	4.06e-05	0.000822	CcSEcCtD
Etoricoxib—Decreased appetite—Docetaxel—melanoma	4.01e-05	0.000812	CcSEcCtD
Etoricoxib—Gastrointestinal disorder—Docetaxel—melanoma	3.98e-05	0.000807	CcSEcCtD
Etoricoxib—Fatigue—Docetaxel—melanoma	3.98e-05	0.000805	CcSEcCtD
Etoricoxib—Pain—Docetaxel—melanoma	3.95e-05	0.000799	CcSEcCtD
Etoricoxib—Constipation—Docetaxel—melanoma	3.95e-05	0.000799	CcSEcCtD
Etoricoxib—PTGS2—lymph node—melanoma	3.93e-05	0.00865	CbGeAlD
Etoricoxib—Feeling abnormal—Docetaxel—melanoma	3.8e-05	0.00077	CcSEcCtD
Etoricoxib—Gastrointestinal pain—Docetaxel—melanoma	3.77e-05	0.000764	CcSEcCtD
Etoricoxib—Abdominal pain—Docetaxel—melanoma	3.65e-05	0.000739	CcSEcCtD
Etoricoxib—Hypersensitivity—Docetaxel—melanoma	3.4e-05	0.000688	CcSEcCtD
Etoricoxib—Asthenia—Docetaxel—melanoma	3.31e-05	0.00067	CcSEcCtD
Etoricoxib—Pruritus—Docetaxel—melanoma	3.27e-05	0.000661	CcSEcCtD
Etoricoxib—Diarrhoea—Docetaxel—melanoma	3.16e-05	0.000639	CcSEcCtD
Etoricoxib—Dizziness—Docetaxel—melanoma	3.05e-05	0.000618	CcSEcCtD
Etoricoxib—Vomiting—Docetaxel—melanoma	2.93e-05	0.000594	CcSEcCtD
Etoricoxib—Rash—Docetaxel—melanoma	2.91e-05	0.000589	CcSEcCtD
Etoricoxib—Dermatitis—Docetaxel—melanoma	2.91e-05	0.000589	CcSEcCtD
Etoricoxib—Headache—Docetaxel—melanoma	2.89e-05	0.000585	CcSEcCtD
Etoricoxib—Nausea—Docetaxel—melanoma	2.74e-05	0.000555	CcSEcCtD
Etoricoxib—MAPK14—Innate Immune System—HRAS—melanoma	2.64e-06	4.82e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Developmental Biology—AKT1—melanoma	2.64e-06	4.82e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—PLA2G6—melanoma	2.63e-06	4.79e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—MAP2K2—melanoma	2.62e-06	4.78e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—melanoma	2.61e-06	4.77e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism of lipids and lipoproteins—PTEN—melanoma	2.61e-06	4.77e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—HIF1A—melanoma	2.61e-06	4.76e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—HPSE—melanoma	2.6e-06	4.74e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Hemostasis—AKT1—melanoma	2.59e-06	4.72e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—CDKN1B—melanoma	2.56e-06	4.67e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—CYP17A1—melanoma	2.56e-06	4.66e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—CUBN—melanoma	2.55e-06	4.65e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Innate Immune System—IL6—melanoma	2.53e-06	4.61e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—melanoma	2.52e-06	4.6e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CD—melanoma	2.52e-06	4.6e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—IL2—melanoma	2.51e-06	4.57e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—KDR—melanoma	2.5e-06	4.56e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—HLA-A—melanoma	2.49e-06	4.55e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—TERT—melanoma	2.49e-06	4.55e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism of lipids and lipoproteins—ALB—melanoma	2.49e-06	4.54e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—RAC1—melanoma	2.49e-06	4.53e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—BSG—melanoma	2.46e-06	4.49e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—SDHD—melanoma	2.46e-06	4.49e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—CSPG4—melanoma	2.46e-06	4.49e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism—ABCB1—melanoma	2.44e-06	4.45e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—CTNNB1—melanoma	2.42e-06	4.41e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—GNA11—melanoma	2.41e-06	4.4e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—FN1—melanoma	2.41e-06	4.39e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—GPAM—melanoma	2.39e-06	4.35e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—HIF1A—melanoma	2.38e-06	4.35e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—CDKN1A—melanoma	2.36e-06	4.31e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—FASN—melanoma	2.36e-06	4.31e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—VCAN—melanoma	2.36e-06	4.3e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—PTEN—melanoma	2.36e-06	4.3e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—NOTCH1—melanoma	2.35e-06	4.29e-05	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—CYP17A1—melanoma	2.35e-06	4.29e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—NFKB1—melanoma	2.35e-06	4.28e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Innate Immune System—AKT1—melanoma	2.33e-06	4.25e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—CYP17A1—melanoma	2.33e-06	4.25e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—SLC5A5—melanoma	2.32e-06	4.24e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—CD80—melanoma	2.31e-06	4.21e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—APC—melanoma	2.3e-06	4.2e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—PIK3CG—melanoma	2.3e-06	4.2e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—KIT—melanoma	2.3e-06	4.2e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—melanoma	2.3e-06	4.19e-05	CbGpPWpGaD
Etoricoxib—CYP2E1—Metabolism—ABCB1—melanoma	2.3e-06	4.19e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—EGF—melanoma	2.28e-06	4.15e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism of lipids and lipoproteins—ALB—melanoma	2.27e-06	4.14e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism—PRKCA—melanoma	2.25e-06	4.09e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—GNAQ—melanoma	2.24e-06	4.09e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—CD44—melanoma	2.24e-06	4.09e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—melanoma	2.23e-06	4.08e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism—ERCC2—melanoma	2.23e-06	4.06e-05	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—GNA11—melanoma	2.22e-06	4.05e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—GNA11—melanoma	2.2e-06	4.01e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CB—melanoma	2.2e-06	4.01e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—melanoma	2.18e-06	3.97e-05	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—FASN—melanoma	2.17e-06	3.96e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—NOS2—melanoma	2.17e-06	3.95e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—BRAF—melanoma	2.16e-06	3.95e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—melanoma	2.16e-06	3.93e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—FASN—melanoma	2.15e-06	3.93e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—CYP1B1—melanoma	2.15e-06	3.92e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—NOTCH1—melanoma	2.15e-06	3.92e-05	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—SLC5A5—melanoma	2.14e-06	3.9e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—SLC5A5—melanoma	2.12e-06	3.86e-05	CbGpPWpGaD
Etoricoxib—CYP2E1—Metabolism—PRKCA—melanoma	2.11e-06	3.85e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—STAT3—melanoma	2.11e-06	3.84e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—IGF1—melanoma	2.11e-06	3.84e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—CD80—melanoma	2.1e-06	3.84e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—NRAS—melanoma	2.1e-06	3.84e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—APC—melanoma	2.1e-06	3.83e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—KIT—melanoma	2.1e-06	3.83e-05	CbGpPWpGaD
Etoricoxib—CYP2E1—Metabolism—ERCC2—melanoma	2.1e-06	3.82e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—EGF—melanoma	2.08e-06	3.79e-05	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—GNAQ—melanoma	2.06e-06	3.76e-05	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—CD44—melanoma	2.06e-06	3.76e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—CD44—melanoma	2.05e-06	3.73e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—GNAQ—melanoma	2.05e-06	3.73e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—MAP2K1—melanoma	2.04e-06	3.71e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—PLA2G6—melanoma	2.03e-06	3.7e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—PIK3CD—melanoma	2.02e-06	3.69e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—MAPK3—melanoma	2.01e-06	3.67e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—melanoma	2e-06	3.65e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Gene Expression—MAPK3—melanoma	2e-06	3.65e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—CYP17A1—melanoma	1.99e-06	3.63e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—melanoma	1.99e-06	3.62e-05	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—CYP1B1—melanoma	1.98e-06	3.61e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—BRAF—melanoma	1.97e-06	3.6e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—melanoma	1.96e-06	3.58e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—CYP1B1—melanoma	1.96e-06	3.58e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Gene Expression—MYC—melanoma	1.95e-06	3.55e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism of lipids and lipoproteins—ALB—melanoma	1.94e-06	3.54e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—FGF2—melanoma	1.94e-06	3.53e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—MAPK1—melanoma	1.92e-06	3.49e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—EGFR—melanoma	1.92e-06	3.49e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—melanoma	1.9e-06	3.46e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—GNA11—melanoma	1.88e-06	3.43e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—MAP2K1—melanoma	1.86e-06	3.39e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—PIK3CD—melanoma	1.85e-06	3.37e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism of lipids and lipoproteins—PIK3CA—melanoma	1.84e-06	3.36e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—FASN—melanoma	1.84e-06	3.36e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—VCAN—melanoma	1.82e-06	3.32e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—MDM2—melanoma	1.81e-06	3.31e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—SLC5A5—melanoma	1.81e-06	3.3e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—KRAS—melanoma	1.81e-06	3.3e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—ERBB2—melanoma	1.79e-06	3.26e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—ABCB1—melanoma	1.77e-06	3.23e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—FGF2—melanoma	1.77e-06	3.22e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—PIK3CB—melanoma	1.76e-06	3.22e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism—PIK3CG—melanoma	1.76e-06	3.21e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—GNAQ—melanoma	1.75e-06	3.19e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—CD44—melanoma	1.75e-06	3.19e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—melanoma	1.73e-06	3.16e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—melanoma	1.71e-06	3.12e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism—PPARG—melanoma	1.7e-06	3.1e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—melanoma	1.7e-06	3.09e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—CXCL8—melanoma	1.69e-06	3.09e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—CYP1B1—melanoma	1.68e-06	3.06e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—PIK3CA—melanoma	1.66e-06	3.03e-05	CbGpPWpGaD
Etoricoxib—CYP2E1—Metabolism—PIK3CG—melanoma	1.66e-06	3.02e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—CDKN1B—melanoma	1.66e-06	3.02e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—MDM2—melanoma	1.65e-06	3.02e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—PRKCA—melanoma	1.63e-06	2.97e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—ERBB2—melanoma	1.63e-06	2.97e-05	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—ABCB1—melanoma	1.63e-06	2.97e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—CASP3—melanoma	1.62e-06	2.96e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—IL2—melanoma	1.62e-06	2.95e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—ERCC2—melanoma	1.62e-06	2.95e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—ABCB1—melanoma	1.62e-06	2.95e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—PIK3CB—melanoma	1.61e-06	2.93e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—CD4—melanoma	1.61e-06	2.93e-05	CbGpPWpGaD
Etoricoxib—CYP2E1—Metabolism—PPARG—melanoma	1.6e-06	2.91e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—CCND1—melanoma	1.58e-06	2.88e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—CTNNB1—melanoma	1.56e-06	2.85e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism—PIK3CD—melanoma	1.55e-06	2.82e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—HRAS—melanoma	1.54e-06	2.81e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—CYP17A1—melanoma	1.54e-06	2.8e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—MMP9—melanoma	1.53e-06	2.8e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—CDKN1A—melanoma	1.53e-06	2.79e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism—ALB—melanoma	1.53e-06	2.78e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—PTEN—melanoma	1.52e-06	2.78e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—NFKB1—melanoma	1.52e-06	2.77e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—CDKN1B—melanoma	1.51e-06	2.75e-05	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—PRKCA—melanoma	1.5e-06	2.73e-05	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—ERCC2—melanoma	1.49e-06	2.71e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—PRKCA—melanoma	1.49e-06	2.71e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—melanoma	1.48e-06	2.7e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—ERCC2—melanoma	1.47e-06	2.69e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—IL6—melanoma	1.47e-06	2.69e-05	CbGpPWpGaD
Etoricoxib—CYP2E1—Metabolism—PIK3CD—melanoma	1.46e-06	2.65e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—GNA11—melanoma	1.45e-06	2.65e-05	CbGpPWpGaD
Etoricoxib—CYP2E1—Metabolism—ALB—melanoma	1.44e-06	2.62e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—CTNNB1—melanoma	1.43e-06	2.6e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—FASN—melanoma	1.42e-06	2.59e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—SLC5A5—melanoma	1.4e-06	2.55e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—CDKN1A—melanoma	1.39e-06	2.54e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—PTEN—melanoma	1.39e-06	2.54e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—ABCB1—melanoma	1.38e-06	2.52e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—VEGFA—melanoma	1.38e-06	2.51e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—STAT3—melanoma	1.36e-06	2.49e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—NRAS—melanoma	1.36e-06	2.48e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—AKT1—melanoma	1.36e-06	2.48e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Gene Expression—AKT1—melanoma	1.35e-06	2.46e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—CD44—melanoma	1.35e-06	2.46e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—GNAQ—melanoma	1.35e-06	2.46e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism—PIK3CB—melanoma	1.35e-06	2.46e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—melanoma	1.34e-06	2.44e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—MAPK3—melanoma	1.3e-06	2.37e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—CYP1B1—melanoma	1.29e-06	2.36e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—PIK3CG—melanoma	1.28e-06	2.33e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—PRKCA—melanoma	1.27e-06	2.32e-05	CbGpPWpGaD
Etoricoxib—CYP2E1—Metabolism—PIK3CB—melanoma	1.27e-06	2.31e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—MYC—melanoma	1.27e-06	2.31e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—ERCC2—melanoma	1.26e-06	2.3e-05	CbGpPWpGaD
Etoricoxib—CYP2E1—Metabolism—PTGS2—melanoma	1.26e-06	2.29e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—STAT3—melanoma	1.24e-06	2.27e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—NRAS—melanoma	1.24e-06	2.26e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—MAPK1—melanoma	1.24e-06	2.26e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—EGFR—melanoma	1.24e-06	2.26e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—PPARG—melanoma	1.23e-06	2.25e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—melanoma	1.22e-06	2.23e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—MAPK3—melanoma	1.19e-06	2.17e-05	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—PIK3CG—melanoma	1.17e-06	2.14e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—KRAS—melanoma	1.17e-06	2.13e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—PIK3CG—melanoma	1.16e-06	2.12e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism—PTEN—melanoma	1.16e-06	2.12e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—MYC—melanoma	1.16e-06	2.11e-05	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—PPARG—melanoma	1.13e-06	2.07e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—MAPK1—melanoma	1.13e-06	2.06e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—EGFR—melanoma	1.13e-06	2.06e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—PPARG—melanoma	1.12e-06	2.05e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—PIK3CD—melanoma	1.12e-06	2.05e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—ALB—melanoma	1.11e-06	2.02e-05	CbGpPWpGaD
Etoricoxib—CYP2E1—Metabolism—PTEN—melanoma	1.1e-06	2e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—PIK3CA—melanoma	1.08e-06	1.96e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—KRAS—melanoma	1.07e-06	1.95e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—ABCB1—melanoma	1.07e-06	1.94e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—melanoma	1.04e-06	1.9e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—TP53—melanoma	1.04e-06	1.9e-05	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—PIK3CD—melanoma	1.03e-06	1.88e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—PIK3CD—melanoma	1.02e-06	1.87e-05	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—ALB—melanoma	1.02e-06	1.86e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—ALB—melanoma	1.01e-06	1.84e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—PIK3CG—melanoma	9.95e-07	1.81e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—HRAS—melanoma	9.95e-07	1.81e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—PIK3CA—melanoma	9.81e-07	1.79e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—PRKCA—melanoma	9.81e-07	1.79e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—PIK3CB—melanoma	9.79e-07	1.78e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—ERCC2—melanoma	9.73e-07	1.77e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—PTGS2—melanoma	9.7e-07	1.77e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—PPARG—melanoma	9.6e-07	1.75e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—IL6—melanoma	9.52e-07	1.74e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—HRAS—melanoma	9.07e-07	1.65e-05	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—PIK3CB—melanoma	9e-07	1.64e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—PIK3CB—melanoma	8.92e-07	1.63e-05	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—PTGS2—melanoma	8.92e-07	1.63e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—PTGS2—melanoma	8.84e-07	1.61e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—AKT1—melanoma	8.78e-07	1.6e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—PIK3CD—melanoma	8.75e-07	1.6e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—IL6—melanoma	8.69e-07	1.58e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—ALB—melanoma	8.64e-07	1.57e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—PTEN—melanoma	8.46e-07	1.54e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism—PIK3CA—melanoma	8.21e-07	1.5e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—AKT1—melanoma	8.01e-07	1.46e-05	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—PTEN—melanoma	7.78e-07	1.42e-05	CbGpPWpGaD
Etoricoxib—CYP2E1—Metabolism—PIK3CA—melanoma	7.73e-07	1.41e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—PTEN—melanoma	7.71e-07	1.41e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—PIK3CG—melanoma	7.68e-07	1.4e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—PIK3CB—melanoma	7.63e-07	1.39e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—PTGS2—melanoma	7.56e-07	1.38e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—PPARG—melanoma	7.41e-07	1.35e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—PIK3CD—melanoma	6.75e-07	1.23e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism—AKT1—melanoma	6.71e-07	1.22e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—ALB—melanoma	6.67e-07	1.22e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—PTEN—melanoma	6.59e-07	1.2e-05	CbGpPWpGaD
Etoricoxib—CYP2E1—Metabolism—AKT1—melanoma	6.32e-07	1.15e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—PIK3CA—melanoma	5.97e-07	1.09e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—PIK3CB—melanoma	5.89e-07	1.07e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—PTGS2—melanoma	5.83e-07	1.06e-05	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—PIK3CA—melanoma	5.49e-07	1e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—PIK3CA—melanoma	5.44e-07	9.92e-06	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—PTEN—melanoma	5.09e-07	9.27e-06	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—AKT1—melanoma	4.87e-07	8.89e-06	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—PIK3CA—melanoma	4.65e-07	8.48e-06	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—AKT1—melanoma	4.48e-07	8.17e-06	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—AKT1—melanoma	4.44e-07	8.1e-06	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—AKT1—melanoma	3.8e-07	6.93e-06	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—PIK3CA—melanoma	3.59e-07	6.54e-06	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—AKT1—melanoma	2.93e-07	5.34e-06	CbGpPWpGaD
